Thermodynamic and Kinetic Characterization of the Interaction between the Ras Binding Domain of AF6 and Members of the Ras Subfamily*

Thomas Linnemann, Matthias GeyerDagger , Birgit K. Jaitner, Christoph Block, Hans Robert KalbitzerDagger , Alfred Wittinghofer, and Christian Herrmann§

From the Abteilung Strukturelle Biologie, Max-Planck-Institut für Molekulare Physiologie, Postfach 102664, 44026 Dortmund and the Dagger  Institut für Biophysik und Physikalische Biochemie, Universität Regensburg, Postfach, 93040 Regensburg, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cellular signaling downstream of Ras is highly diversified and may involve many different effector molecules. A potential candidate is AF6 which was originally identified as a fusion to ALL-1 in acute myeloid leukemia. In the present work the interaction between Ras and AF6 is characterized and compared with other effectors. The binding characteristics are quite similar to Raf and RalGEF, i.e. nucleotide dissociation as well as GTPase-activating protein activity are inhibited, whereas the intrinsic GTPase activity of Ras is unperturbed by AF6 binding. Particularly, the dynamics of interaction are similar to Raf and RalGEF with a lifetime of the Ras·AF6 complex in the millisecond range. As probed by 31P NMR spectroscopy one of two major conformational states of Ras is stabilized by the interaction with AF6. Looking at the affinities of AF6 to a number of Ras mutants in the effector region, a specificity profile emerges distinct from that of other effector molecules. This finding may be useful in defining the biological function of AF6 by selectively switching off other pathways downstream of Ras using the appropriate effector mutant. Notably, among the Ras-related proteins AF6 binds most tightly to Rap1A which could imply a role of Rap1A in AF6 regulation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cellular functions like growth and differentiation are regulated by a complex network of interacting proteins with either enzymatic or adaptor functions. Ras plays a central role in this signaling network. It is bound to GDP in its resting state and bound to GTP after activation (1). Only this activated form can interact with effector molecules like Raf kinase, RalGEF, and PI(3)kinase1 (2). A variety of incoming signals is directed to Ras activation, and this in turn triggers the activation of different signal pathways that lead to diverse consequences such as induction of DNA transcription, inhibition of apoptosis, and/or cytoskeletal rearrangements (3). Synergism with other signaling events or inhibition by competing pathways may supplement or modulate the signal amplitude resulting in a distinct effect. When Ras binds to the effectors they become activated by different and not fully understood mechanisms. This leads to the activation of other molecules located further downstream in the signal cascade. There are other small GTP-binding proteins closely related to Ras like Rap1A/2A, TC21, and R-Ras which also bind to the Ras effectors. So far little is known about their biological functions.

The effectors c-Raf-1 (4), RalGEF (5), and PI(3)kinase (6, 7) have been shown to become activated upon Ras binding. For other possible Ras targets like Rin1/2 (8), PKCzeta (9), Krit (10), or Nore1 (11) the requirements for a Ras effector have been fulfilled in that they bind in a GTP-dependent manner and do not bind to the effector mutant Ras(D38A), but functional data are missing for these proteins. Recently, AF6 was discovered as another putative effector of Ras (12, 13). This protein was originally described as a fusion partner of ALL-1 in acute myeloid leukemia (14). AF6 is a homolog of Canoe in Drosophila which is genetically linked to the Notch cascade and other signaling pathways (15). Canoe and AF6 have the PDZ domain which in the case of AF6 was shown to bind to the Eph3B receptor (16). The amino terminus of AF6 was identified as the Ras-binding site (12, 13). ZO-1, a protein involved in the formation of tight junctions, also binds to AF6 close to the amino terminus thereby competing with Ras binding (17). These data suggest a participation of AF6 in the regulation of cell-cell contacts via a Ras-modulated interaction with ZO-1. Further evidence for this role of AF6 comes from the discovery of l-Afadin, a larger AF6 splicing variant in rat which additionally carries an actin-binding site at the carboxyl terminus (18). l-Afadin appears to serve as a linker between the actin cytoskeleton and the plasma membrane in adherens junctions. A recent finding that the de-ubiquitinating enzyme Fam (fat facets in mouse) interacts with AF6 suggests that the AF6 action is based on the turnover of participating proteins (19).

In contrast to the well characterized effectors Raf, RalGEF, and PI(3)kinase, AF6 is a protein with no enzymatic function. It seems to serve as a scaffolding component for protein complexes. This would represent a new type of Ras effector because Ras binding in this case does not lead to the activation of the enzymatic activity of the effector. In contrast, for the regulation of Raf only transient Ras binding is necessary. Therefore in this work the Ras binding domain (RBD) of AF6 is defined, and its interaction with Ras is characterized by thermodynamic and kinetic parameters and compared with the binding behavior of the RBDs of Raf and RalGEF. Since for other effectors highly specific binding to different Ras proteins was demonstrated, all members of the Ras subfamily are included in this investigation.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cloning-- Rat and human AF6 fragments were amplified via standard polymerase chain reaction methods, ligated into pGEX and yeast plasmids, respectively, and transformed into Bl21 and DH5alpha . Mutations were introduced in Ras by standard polymerase chain reaction protocols (20). All clones were verified by sequencing (ABI-Prism, Perkin-Elmer).

Yeast Two-hybrid Assay-- Yeast two-hybrid studies were performed in Saccharomyces cerevisiae Y190 according to the system of Chevray and Nathans (21). Briefly, competent Y190 cells were prepared as described (22) and cotransformed with 1 µg of each of the two-hybrid vectors. Efficient transformation was checked on synthetic medium lacking leucine and tryptophan (-Leu/Trp). Transformed yeast cells were grown on synthetic medium lacking leucine, tryptophan, and histidine containing 25 mM 3-amino-1,2,3-triazole (-Leu/Trp/His, Sigma) for the indicated time in order to detect interaction between Ras and the AF6 constructs (Fig. 1). 2% glucose was used in all media as the carbon source. beta -Galactosidase activity was measured by filter-lifting the yeast cells grown on -Leu/Trp/His medium and staining the yeast cells with 1 mg/ml X-Gal at 37 °C for the indicated time.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   Interaction of amino-terminal AF6 fragments with Ras in the yeast two-hybrid assay. Following AF6 constructs cloned into pPC86 were probed against RasG12V-(1-166) in pPC97: a, aa 1-141, b, aa 1-149, c, aa 1-170, d, aa 30-141, e, aa 36-206 (a-d are from the rat sequence and e is from human). Panel A, 3 days' growth on -Leu/Trp agar plates. Panel B, 3 days' growth on -Leu/Trp/His agar plates after the colonies were replated from the -Leu/Trp agar plates. Panel C, X-Gal test with the grown yeasts from panel B. The yeasts were incubated for 70 min with X-Gal after filter lifting them from the -Leu/Trp/His agar plates.

Proteins-- The Escherichia coli strain Bl21 was grown in standard I medium (Merck), and the expression of the pGEX plasmid encoding the glutathione S-transferase/AF6-RBD fusion protein was induced by the addition of 0.1 mM isopropyl-beta -D-thiogalactoside after OD = 0.6 was reached. The culture was incubated at 30 °C for 4 h and then centrifuged. The resuspended cell pellet was sonicated, and the lysate was cleared by centrifugation (32,000 × g). The insoluble and soluble fractions were analyzed by SDS-polyacrylamide gel electrophoresis indicating that the glutathione S-transferase/AF6-RBD fusion protein (42 kDa) is readily soluble (Fig. 2, lanes 1 and 2). The glutathione S-transferase fusion was purified according to the standard procedure by means of a glutathione-Sepharose column (Amersham Pharmacia Biotech). After protein cleavage by thrombin (10 units/ml, overnight) and elution of AF6-RBD from the column (Fig. 2, lanes 3-6), this protein fragment was further purified by size exclusion chromatography (Superdex 75, Amersham Pharmacia Biotech). The protein fractions were analyzed for purity by SDS-polyacrylamide gel electrophoresis, pooled, and concentrated to 20 mg/ml by ultrafiltration (Vivaspin 15, Vivascience), shock-frozen in liquid nitrogen, and stored at -80 °C. The preparation of the Ras proteins and the nucleotide exchange procedure are described (23). The catalytic fragment of p120-GAP comprising residues 714-1047 was kindly provided by R. Ahmadian (see Ref. 24).


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 2.   Purification of AF6-RBD visualized by a Coomassie-stained SDS-polyacrylamide gel. Bacterial lysate after centrifugation: lane 1, pellet; lane 2, supernatant; lane 3, GSH column flow-through; lane 4, protein eluted with GSH from GSH column after 12 h thrombin incubation; lane 5, AF6-RBD eluted with buffer; lane 6, AF6 RBD after gel filtration. Lane M, marker proteins with molecular masses as indicated (SDS 7; Sigma).

Experimental Techniques-- Protein concentrations were measured using the dye assay described by Bradford (25). Bovine serum albumin was used for calibration. Nucleotide concentrations in the GTPase assay were quantified by HPLC (Beckman) using a reversed phase C18 column (ODS Ultrasphere, Beckman). For further details see Lenzen et al. (26). Fluorescence measurements were carried out on a spectrofluorimeter (Fluoromax, Spex) equipped with a thermostatting device. For stopped-flow measurements an SM-17 apparatus (Applied Photophysics) was used. Rate constants can reliably be measured up to 500 s-1 since the dead time for the mixing of two solutions is in the range of 1-2 ms. Ras·mant-GppNHp was mixed with AF6-RBD in more than 5-fold molar excess in order to have pseudo-first order conditions for the association. Accordingly, the fluorescence traces monitored were fitted with an exponential curve yielding kobs. Mant nucleotides were excited at 360 nm, and the fluorescence was monitored through a 408-nm cut-off filter. If not indicated otherwise, all experiments were carried out in a buffer containing 20 mM Tris/HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, and 1 mM dithiothreitol. The proteins were transferred into other buffers using Nap-5 columns (Amersham Pharmacia Biotech).

Differential scanning calorimetry was performed with a VP-DSC (MicroCal Science). Evaluation of the data was done with the manufacturer's software (Microcal Origin 4.1). Briefly, the buffer base line was subtracted from the experimental curve. According to the two-state model a curve was fitted to the experimental data including Delta Cp effects.

The NMR spectra were recorded on a Bruker DMX-500 spectrometer operating at a phosphorous resonance frequency of 202 MHz. The signal was referenced to 85% phosphoric acid which was sealed in a glass sphere immersed in the sample. Further experimental conditions are given in Fig. 8.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Minimization of the AF6-RBD-- For the biochemical and structural characterization of the interaction of AF6 with Ras and other small GTPases, bacterial synthesis of recombinant protein at reasonable levels is required. In order to define a soluble and stable protein fragment which comprises the minimal Ras binding domain of the AF6 protein, different constructs were tested for their ability to bind to Ras. In a first step this was done semi-quantitatively by the double hybrid assay as described by Jaitner et al. (27). RasG12V truncated by the 23 carboxyl-terminal amino acids was introduced into pPC97 and cotransformed with different AF6 constructs ligated into pPC86. The construct starting from the amino terminus (amino acids 1-170) as described by van Aelst et al. (12) showed a strong signal in this system (Fig. 1) indicating a strong interaction with Ras. These colonies grow within 3 days, and the stain seen in Fig. 1, panel C, developed after 70 min incubation with X-Gal. Shortening this fragment by 21 and 29 amino acids at its carboxyl-terminal end, respectively, improved binding significantly (Fig. 1, panel B). The X-Gal response is similar to that of Ras and Raf-RBD which are known to interact strongly (27). Under the same conditions the sequence of the RBD of AF6 (aa 36-206) reported earlier (13) did not support growth in the Y190 strain. A similar result was obtained with another amino-terminal truncated sequence (aa 30-141) which contains all residues from the predicted RBD of AF6 (28). The latter showed only small colonies after 9 days of growth which gave a poor X-Gal stain after overnight incubation (data not shown).

The DNAs encoding different AF6 constructs, namely residues 1-84, 13-133, 30-141, and 1-141, were transferred into pGEX-4T3 vectors and expressed in the bacterial strain BL21 in order to check the integrity and the solubility of the protein fragments. The two former fragments were poorly soluble and were partly degraded in E. coli. From the two latter protein fragments 30-141 bound much less strongly to Ras than 1-141 (assay see below). From these observations we concluded that the Ras binding domain (RBD) of AF6 requires residues 1-141 for full integrity and strong binding to Ras. This fragment is defined as AF6-RBD and is used for further biochemical experiments in this study. By size exclusion chromatography and comparison to the elution volumes of standard proteins (data not shown), it was demonstrated that AF6-RBD is a homogeneously monomeric protein.

To check the stability of AF6-RBD and to show that it constitutes a stable folding domain, it was further characterized by differential scanning calorimetry. A solution of AF6-RBD was heated from 20 to 80 °C at 70 °C/h, and unfolding was monitored with the change in the heat capacity Cp (Fig. 3). The reversibility of the unfolding transition in a solution at pH 9.0 was reasonably high for a thermodynamic analysis, i.e. 85% recovery of folded protein after each scan. This analysis was carried out under the assumption of a two-state equilibrium, i.e. the protein is either in the native, folded state, or in the unfolded state, and no intermediates occur (29). Such a behavior is seen for most small proteins which constitute a single cooperativity unit. The fit to the data yielded Delta Hu = 62.7 kcal/mol for the enthalpy of unfolding and Tm = 56,1 °C for the melting temperature. The scanning rate had no influence on the melting point and the enthalpy. At 40 and 90 °C/h 60 and 95% reversibility of unfolding was observed, respectively, which can be explained by the different times the unfolded protein was kept at high temperature. The quasi-reversible unfolding transition may be taken as additional evidence for the integrity of AF6-RBD.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   Differential scanning calorimetry with AF6-RBD. 0.2 mg/ml AF6-RBD in 20 mM glycine (pH 9.0 at 20 °C), 100 mM NaCl, and 1 mM beta -mercaptoethanol was scanned at a rate of 70 °C/h. A theoretical curve (dashed line) was fitted to the experimental temperature dependence of the heat capacity (solid line). The calculated base line (dotted line) is also shown. The best fit parameters for this experiment were Tm = 56.1 °C, Delta Hu(Tm) = 62.7 kcal/mol, and Delta Cp = 0.3 kcal/mol/K.

AF6-RBD Binding to Ras Proteins-- In our earlier studies on the interaction of Ras proteins with effector RBDs, we made use of the inhibition of nucleotide dissociation from Ras upon effector binding (30). AF6-RBD also inhibits nucleotide dissociation from Ras. In this GDI assay Ras is quantitatively loaded with the non-hydrolyzable GTP analog with a fluorescent label attached to the ribose moiety. The dissociation of this nucleotide mant-GppNHp is initiated by adding a 1000-fold excess of unlabeled GppNHp. The fluorescence decay due to quasi-irreversible mant-GppNHp dissociation is monitored and fitted by an exponential function. The obtained rate constants are plotted versus AF6-RBD concentration and a curve fitted according to Equation 2 yields the dissociation constant Kd as defined in Equation 1. Equation 2 may be applied since the equilibration of the Ras·AF6 complex is fast compared with the nucleotide dissociation as shown below. The Ras protein, the nucleotide, and the effector AF6-RBD are abbreviated by R, N, and E, respectively, and k-1 and k-2 represent the nucleotide dissociation rate constants from Ras alone and from the Ras·effector complex, respectively. Index 0 denotes total concentrations.
K<SUB>d</SUB>=<FR><NU>[R−N]*[E]</NU><DE>[R−N−E]</DE></FR> (Eq. 1)
k<SUB><UP>obs</UP></SUB>=k<SUB><UP>−</UP>1</SUB>−(k<SUB><UP>−</UP>1</SUB>−k<SUB><UP>−</UP>2</SUB>) (Eq. 2)
 · <FR><NU>([R<SUB><UP>o</UP></SUB>]+[E<SUB><UP>o</UP></SUB>]+K<SUB>d</SUB>)−<RAD><RCD>([R<SUB><UP>o</UP></SUB>]+[E<SUB><UP>o</UP></SUB>]+K<SUB>d</SUB>)<SUP>2</SUP>−4 · [R<SUB><UP>o</UP></SUB>] · [E<SUB><UP>o</UP></SUB>]</RCD></RAD></NU><DE>2 · [R<SUB><UP>o</UP></SUB>]</DE></FR>
In Fig. 4 the dependence of the observed nucleotide dissociation rate constant on the AF6-RBD concentration is shown for Rap1A and Ras. The Kd values obtained from these data and also for Rap2A, R-Ras, and TC21 are listed in Table I, and it is remarkable that Rap1A binds more than 10-fold more tightly to AF6-RBD than Ras and Rap2A, respectively.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   GDI assay with AF6-RBD. Dissociation rate constants of mant-GppNHp from Ras (upper panel) and Rap1A (lower panel) in dependence of AF6-RBD concentration at 37 °C. The rate constants were measured as described in the text, and the Kd values obtained from the fit according to Equation 2 are listed in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kd values for AF6-RBD and members of the Ras subfamily
The data were obtained with the GDI method with mantGppNHp and mantGDP bound to the Ras protein. For some proteins Kd > 100 µM is indicated. This means that up to AF6-RBD concentrations of 100 µM less than 50% inhibition of nucleotide dissociation is observed.

It was also possible to measure the affinity between Ras and AF6-RBD by means of direct fluorescence titration. At 20 °C the fluorescence of Ras·mant-GppNHp drops by 12% on saturation with AF6-RBD as shown in Fig. 5, upper panel. In the lower panel a curve is fitted to the titration data according to Equation 2 where k-1 and k-2 are replaced by the maximum and minimum fluorescence values, respectively, and kobs is replaced by the relative fluorescence. The Kd value of 1.8 µM obtained from this fit is in good agreement with the result of 3.0 µM from the GDI assay regarding the difference in temperature. At 37 °C the titration is impossible since there is almost no change in fluorescence detectable. On addition of 100 µM AF6-RBD to Ras·mant-GDP no change in fluorescence is seen (Fig. 5, upper panel). As for the GDI data this is explained by the lack of binding at this concentration which means that the affinity of AF6 to the GDP form of Ras is at least 33-fold lower compared with the GTP form.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Fluorescence titration. Upper panel, fluorescence spectra (lambda ex = 360 nm) of 0.5 µM mant-GppNHp loaded Ras in the absence (a) and in the presence (b) of 20 µM AF6-RBD and correspondingly for Ras·mant-GDP (c and d, respectively) at 20 °C. Lower panel, Ras·mant-GppNHp was titrated against AF6-RBD at 20 °C (lambda ex = 360 nm, lambda em = 440 nm).

Evidence has accumulated during the last few years that Ras signaling branches out into several distinct pathways (for review see Ref. 30) the output of which may depend on the type of the cell or on the synergism with other stimuli. By cell transformation studies it was shown that certain mutations in the Ras effector region lead to abrogation of signaling to distinct effectors. The mutants T35S, E37G, and Y40C appear to cause discrimination between the effectors Raf, RalGEF, and PI(3)kinase (31-35). As an example T35S is believed to merely activate Raf, E37G only activates RalGEF, whereas Y40C is reported to activate only PI(3)kinase. D38A is the most prominent effector mutant of Ras which decreases the affinity to Raf- and RalGEF-RBD, respectively, by approximately 2 orders of magnitude (23, 30). All these mutants were tested for their ability to bind AF6-RBD, and the Kd values obtained by the GDI method are listed in Table I. The mutations T35S and Y40C, respectively, prevent interaction with AF6-RBD up to a concentration of 100 µM. In contrast, the Ras mutant E37G decreases the affinity only 10-fold, and the same small decrease of complex stability is found for D38A. Mutation at position 31 which is known to be a strongly discriminative amino acid of Ras and Rap1A for Raf and RalGEF binding (23, 36-38) did not change the affinity to AF6.

Effect on GTP Hydrolysis-- As AF6-RBD has an influence on the nucleotide binding to Ras, it was worthwhile to look at the effect on GTP hydrolysis activity of Ras. At 37 °C 50 µM Ras loaded with GTP was incubated in the absence and in the presence of saturating amounts of AF6-RBD (100 µM). The time course of GTP hydrolysis by Ras was monitored by HPLC analysis of the nucleotides. The data obtained in Fig. 6 were fitted according to first order kinetics. For both experiments the same rate constants were calculated (0.03 min-1) demonstrating that AF6-RBD binding to Ras does not change its GTPase activity.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   The influence on GTPase activity. 50 µM Ras·GTP was incubated at 37 °C, and aliquots were analyzed for nucleotide concentrations by HPLC. Solid symbols indicate the presence of 4 nM of the catalytic fragment of GAP, and the triangles represent the experiments in the presence of 100 µM AF6-RBD.

Effector molecules and GAPs bind to overlapping sites on Ras (37, 39, 40). Accordingly, the catalytic activity of GAP is inhibited by Raf and RalGEF (21). In order to check if AF6 binds to Ras in the same manner as the other effectors, the inhibition of GAP was investigated. 50 µM Ras·GTP and 4 nM of the catalytic fragment of GAP were incubated at 37 °C, and the nucleotide concentrations were probed at short time intervals (Fig. 6). The addition of AF6-RBD reduced the catalytic activity of GAP suggesting but not proving competitive binding of AF6 and GAP. In the presence of saturating amounts of AF6-RBD the binding of GAP is completely inhibited as the rate of GTP hydrolysis corresponds to the intrinsic activity of Ras (Fig. 6).

Binding Kinetics-- When Ras binds to Raf, RalGEF, or PI(3)kinase, it activates the enzymatic activity of these effector molecules by not fully understood mechanisms. Although Ras binds tightly to Raf, it was shown that these proteins form a short-lived complex (41, 42). This highly dynamic behavior of the Ras·Raf complex could be important for the activation of Raf kinase activity or for the down-regulation of Ras by GAP. For the Ras·RalGEF complex similar interaction dynamics are observed.2

The binding kinetics of Ras/AF6 were investigated by means of the stopped-flow technique. The fluorescence change observed on binding of AF6-RBD to mant-GppNHp-loaded Ras proteins as described above (Fig. 5) was used as detection signal. For Ras as well as for Rap1A the observed rate constant kobs showed a linear dependence on the concentration of AF6-RBD up to 15 µM. From the linear slope fitted to the data kon, the apparent association rate constant, is obtained, and the intercept corresponds to the dissociation rate constant koff. The dissociation rate constant can be measured more accurately by displacement experiments. Ras·mant-GppNHp is displaced from the complex with AF6-RBD by addition of a large molar excess of non-labeled Ras·GppNHp. In a typical experiment a solution containing 0.5 µM Ras·mant-GppNHp and 6 µM AF6-RBD was mixed with 60 µM Ras·GppNHp. The observed rate constant in this case is governed by the dissociation process. The dissociation rate constants obtained by this method agree with the intercepts mentioned above. In the case of Rap1A the dissociation rate constant is smaller than the experimental error for the intercept. Here the dissociation rate constant can only be obtained from the displacement experiments. At 26 °C lifetimes of the AF6·RBD complexes with Ras and Rap1A of 10 and 100 ms are calculated, respectively. This is similarly short-lived as the Ras·Raf-RBD complex (42). The results for the temperature range between 10 and 26 °C are listed in Table II together with the ratios koff/kon which agree well with the Kd values reported in the upper section.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Stopped-flow kinetics
Rate constants are given for the interaction of AF6-RBD with Ras.mantGppNHp and Rap.mantGppNHp, respectively, obtained by stopped-flow experiments.

From the temperature dependence of the rate constants the energies of activation for complex dissociation and association Eaoff and Eaon, respectively, can be obtained. According to the Arrhenius equation the energies of activation Eaoff = 16 kcal/mol and Eaon = 14 kcal/mol for Ha-Ras and Eaoff = 9.5 kcal/mol and Eaon = 10 kcal/mol for Rap1A are calculated, respectively.

At room temperature and at concentrations higher than 20 µM kobs is too large to be measured by means of the stopped-flow technique. However, at 10 °C saturation of Ras/AF6 binding kinetics is observed at higher concentrations which is an indication of a two-step binding process. The formation of an initial weak complex is followed by a conformational rearrangement leading to tight binding. Under the assumption that the dissociation of the initial complex is fast compared with its conformational rearrangement, the observed rate constant for the two-step binding process is described by Equation 3. K1 is the association constant for the initial weak complex, and k+2 and k-2 represent the rate constants of the forward and backward conformational rearrangements, respectively. Note that at concentrations far below 1/K1 Equation 3 can be approximated by a linear equation (see above).
k<SUB><UP>obs</UP></SUB>=<FR><NU>k<SUB><UP>+</UP>2</SUB></NU><DE>1+1/(K<SUB>1</SUB> · [<UP>RBD</UP>])</DE></FR>+k<SUB><UP>−</UP>2</SUB> (Eq. 3)
In Fig. 7 the observed rate constants measured under pseudo-first order conditions are plotted versus AF6-RBD concentration. From the fit to the data according to Equation 3 a value of K1 = 25,000 M-1 is obtained which corresponds to a dissociation constant of the initial encounter complex of 40 µM. The maximum k+2 + k-2 is reached at 310 s-1. For Rap1A no sign of saturation of AF6-RBD binding kinetics could be observed up to 50 µM where the upper limit for stopped-flow experiments of kobs = 500 s-1 is reached (data not shown).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7.   Saturation of the binding kinetics. In a thermostatted (10 °C) stopped-flow apparatus Ras·mant-GppNHp (0.5 µM) was mixed with AF6-RBD at concentrations as indicated. Fluorescence was excited at 360 nm and monitored through a cut-off filter of 408 nm. The data are fitted according to Equation 3.

31P NMR Studies on the Ras·AF6-RBD Complex-- By 31P NMR experiments it was shown previously that the GppNHp-bound form of Ras exists in two conformational states (43) which is reflected by the band splitting of the alpha - and beta -phosphorus resonances in the bottom panel of Fig. 8. The higher populated state (61%) was interpreted as the conformation with the effector loop (switch I) in close proximity to the phosphate groups exhibiting a ring current shift of the Tyr-32 side chain onto the phosphorus atoms (state 2). In the other state Tyr-32 is pointed away from the nucleotide (state 1). From the bottom to the top panel of Fig. 8 increasing amounts of AF6-RBD are added to a Ras·GppNHp solution. The change of the alpha - and beta -phosphorus resonances reflects a shift from state 1 to state 2. At saturation only state 2 is populated indicating a stabilization of this conformation by AF6-RBD binding.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 8.   31P NMR spectra of a titration series of AF6-RBD to Ras· GppNHp. 500 MHz spectra of Ras·GppNHp at 1 mM and AF6-RBD from bottom to top panel at 0, 0.2, 0.5, and 1 mM, respectively, at 5 °C. The resonances between -12 and -11 ppm correspond to Palpha (where P indicates phosphate), between -4 and -2 to Pbeta , and at -0.3 to Pgamma . The peak at 2.3 ppm originates from free phosphate ions.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Previously, AF6 was identified as a potential Ras target (12, 13) which would add to the list of well established effectors like Raf kinase, RalGEF, and PI(3)kinase. It was also demonstrated that AF6 binds to tight junctions in epithelial cells via the interaction of the AF6 amino terminus with ZO-1 which appears to be regulated by Ras (17). This mechanism would further increase the complexity of Ras signaling and could explain the perturbation of cell-cell contacts induced by activated Ras. Activation of some Ras effectors by Rap, R-Ras, or TC21 was also demonstrated (44-46). Therefore, quantitative knowledge about the interaction of AF6 with all putative partners is necessary in order to estimate physiological consequences like inhibition or synergism in the context of the cell where all Ras proteins can be present. Furthermore, information about the dynamics of protein-protein interactions could be an important criterion for the assessment of signaling or scaffolding complexes. In this work the interactions between AF6 and members of the Ras subfamily have been characterized by biophysical methods. A stable protein fragment constituting the RBD of AF6 was defined, and its binding specificity and the dynamic behavior of Ras interaction were investigated.

Apart from Ras and Rap1A (12, 13) no other Ras proteins had been reported to interact with AF6 so far. The data presented here demonstrate that the closely related Rap2A, TC21, and R-Ras also bind to AF6-RBD. Moreover, like the RBDs of the effectors Raf and RalGEF, the RBD of AF6 showed different affinities to the various Ras proteins. Intriguingly, AF6 forms the most stable complex with Rap1A which is more than 10 times tighter than with Ras, Rap2A, TC21, and R-Ras, respectively, as shown in Table I. For Rap1 an influence on the regulation of cell morphology via the cytoskeleton was shown in various organisms like yeast (47, 48), Neurospora crassa (49), Dictyostelium (50), and in the Swiss 3T3 cell line (51). It is uncertain whether the affinity of the Ras·effector complex correlates with its physiological importance, but it will be worthwhile to investigate the biological function of the Rap1A-AF6 interaction.

When specificity is discussed it should be stressed that Rap2A and Ras have the same affinity. This is surprising since throughout the effector region (residues 20-45) the homology is higher between Rap1A and -2A than between Rap1A and Ras (see Fig. 9). Residues that are different between Rap1A and -2A are the same for Rap1A and Ras, and residues different between Rap1A and Ras are the same for Rap1A and -2A. So, the observed affinities could be due to subtle differences of the Rap1A and -2A conformations that are not obvious from the primary sequence. The involvement of switch II of Ras in AF6-RBD binding is unlikely since two mutants in this region, E62A and E63A, do not alter significantly the affinity that is also observed for Raf and RalGEF binding.2


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 9.   Primary sequence alignment of the effector region of Ras-like proteins. The one-letter code for amino acids is used to compare the residues of the Ras relatives in the effector region (residues 32-40). Dots represent conserved amino acids.

Partial loss of function mutations of Ras were reported from various investigators. These particular mutants have been found to bind and activate only distinct effectors and so they are useful for reducing the complexity of Ras signaling in biological experiments. The affinities of these Ras mutants to AF6-RBD were quantified (Table I), and together with the affinities to the different Ras proteins one may say that the binding specificity of AF6 has a similar profile as RalGEF. Exceptions though are represented by the Ras/Rap residue 31 and by D38A. These findings may be helpful for the design of experiments addressing the biological function of AF6. By the appropriate design of a Ras or Rap1A mutant, AF6 binding may be preferred (e.g. E31K, D38A) or specifically blocked (e.g. T35S, Y40C), respectively.

Proteins in general are constituted of largely independent building blocks with distinct functions like catalytic activity or docking to other proteins (e.g. Refs. 52 and 53). Our studies were done with only a fragment of the AF6 protein implying that only this part of the protein is responsible for Ras binding. Support for this assumption may be taken from our earlier findings with Raf where the binding constants of several RBD mutants showed a good correlation with the activation of Raf by Ras and with the binding of Ras to full-length Raf carrying the same mutations as probed by a reporter gene assay in a mammalian cell line and by the double hybrid method in yeast cells, respectively (54, 55).

From kinetic studies with Raf-RBD it was concluded that the association with Ras occurs in two steps (42). The formation of an initial complex with low stability is followed by a conformational rearrangement of the proteins leading to tighter binding (induced fit). This is indicated by the saturation of the binding kinetics at high concentrations where the rate of the second step becomes rate-limiting. This behavior is also observed for the association of Ras and AF6-RBD. In summary, the mechanism of Ras binding is similar for AF6-RBD and Raf-RBD, and particularly, the complexes are similarly short-lived. The difference in nature of an enzymatically acting effector like Raf or RalGEF and a potential scaffolding protein like AF6 is not reflected in the dynamics of complex formation and dissociation of their RBDs.

Further evidence for a similar interaction is taken from the influence of the Ras-AF6-RBD interaction on the dynamics of the effector region as probed by 31P NMR spectroscopy. Notably, no shift of the phosphorus resonances occurs when AF6-RBD binds to Ras which indicates that AF6-RBD attaches to Ras remote from the nucleotide-binding site like the RBDs of Raf and RalGEF. Moreover, after addition of saturating AF6-RBD concentrations, the band splitting disappears in favor of the state where Tyr-32 is located in closer proximity to the nucleotide. The same stabilization of this conformational state was reported for the Ras/Raf and Ras-RalGEF interactions.

In conclusion, the members of the Ras superfamily recognize AF6 in a manner characteristic for all effectors, and Rap1A shows the highest affinity. Whereas the RBDs of Raf and RalGEF have the same size and despite their low sequence homology show the same structural fold, the RBD of AF6 with 141 residues is significantly larger. Nevertheless, the binding characteristics as probed by mutagenic and kinetic studies as well as by 31P NMR spectroscopy are quite similar for all these effector RBDs. The influence of AF6 on the nucleotide dissociation from Ras and the competition of AF6 and GAP strongly suggest the same type of interaction as Raf and RalGEF. Specific differences are observed, however, such as the different contributions to binding by residues 31 and 38 from Ras. Structural results must be waited for in order to compare the Ras-AF6 interaction on an atomic level to the other RBDs. It will be interesting to see if AF6 is another effector with the same RBD topology as Raf and RalGEF, how the additional residues are accommodated, and how ZO-1 binding to AF6 or the interaction with other proteins is regulated by Ras or its relatives.

    ACKNOWLEDGEMENTS

We thank Linda vanAelst and Kozo Kaibuchi for kindly providing the cDNA of rat AF6 (aa 1-170) and human AF6, respectively.

    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft Grant He 2679/1.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 49 231 1206 351; Fax: 49 231 1206 230; E-mail: christian.herrmann{at}mpi-dortmund.mpg.de.

2 T. Linnemann and C. Herrmann, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: PI(3)kinase, phosphatidylinositol 3-kinase; GDI, guanine nucleotide dissociation inhibition; GppNHp, guanyl-5'-yl imidodiphosphate; mant, 2',3'-(N-methylanthraniloyl), a fluorophor attached at 2'- or 3'-position to the nucleotide; HPLC, high pressure liquid chromatography; RalGEF, Ral guanine nucleotide exchange factor; RBD, Ras binding domain; X-Gal, 5-bromo-4-chloro-3-indolyl-beta -galactopyranoside; aa, amino acids; GAP, GTPase-activating protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Bourne, H. R., Sanders, D. A., and McCormick, F. (1990) Nature 348, 125-132[CrossRef][Medline] [Order article via Infotrieve]
  2. Marshall, C. J. (1996) Curr. Opin. Cell Biol. 8, 197-204[CrossRef][Medline] [Order article via Infotrieve]
  3. Bos, J. L. (1998) EMBO J. 17, 6776-6782[Abstract/Free Full Text]
  4. Vojtek, A. B., and Der, J. D. (1998) J. Biol. Chem. 273, 19925-19928[Free Full Text]
  5. Urano, T., Emkey, R., and Feig, L. A. (1996) EMBO J. 15, 810-816[Abstract]
  6. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Vicana, P., Downward, J., and Parker, P. J. (1994) Curr. Biol. 4, 798-806[Medline] [Order article via Infotrieve]
  7. Rodriguez-Vicana, P., Warne, P. H., Dhand, R., VanHaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532[CrossRef][Medline] [Order article via Infotrieve]
  8. Han, L., and Colicelli, J. (1995) Mol. Cell. Biol. 15, 1318-1323[Abstract]
  9. Diaz-Meco, M. T., Lozano, J., Municio, M. M., Berra, E., Frutos, S., Sanz, L., and Moscat, J. (1994) J. Biol. Chem. 269, 31706-31710[Abstract/Free Full Text]
  10. Serebriiskii, I., Estojak, J., Sonoda, G., Testa, J. R., and Golemis, E. A. (1997) Oncogene 15, 1043-1049[CrossRef][Medline] [Order article via Infotrieve]
  11. Vavvas, D., Li, X., Avruch, J., and Zhang, X. (1997) J. Biol. Chem. 273, 5439-5442[Abstract/Free Full Text]
  12. van Aelst, L., White, M., and Wigler, M. H. (1994) Cold Spring Harbor Symp. Quant. Biol. 59, 181-186[Medline] [Order article via Infotrieve]
  13. Kuriyama, M., Harada, N., Kuroda, S., Yamamoto, T., Nakafuku, M., Iwamatsu, A., Yamamoto, D., Prasad, R., Croce, C., Canaani, E., and Kaibuchi, K (1995) J. Biol. Chem. 271, 607-610[Abstract/Free Full Text]
  14. Prasad, R., Gu, Y., Alder, H., Nakamura, T., Canaani, O., Saito, H., Huebner, K., Gale, R. P., Nowell, P. C., Kuriyama, K., Miyazaki, Y., Croce, C. M., and Canaani, E. (1993) Cancer Res. 53, 5624-5628[Abstract]
  15. Miyamoto, H., Nihonmatsu, I., Kondo, S., Ueda, R., Togashi, S., Hirata, K., Ikegami, Y., and Yamamoto, D. (1995) Genes Dev. 9, 612-625[Abstract]
  16. Hock, B., Böhme, B., Karn, T., Yamamoto, T., Kaibuchi, K., Holtrich, U., Holland, S., Pawson, T., Rübsamen-Waigmann, H., and Strebhardt, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9779-9784[Abstract/Free Full Text]
  17. Yamamoto, T., Harada, N., Kano, K., Taya, S., Canaani, E., Matsuura, Y., Mizoguchi, A., Ide, C., and Kaibuchi, K. (1997) J. Cell Biol. 139, 785-795[Abstract/Free Full Text]
  18. Mandai, K., Nakanishi, H., Satoh, H., Obaishi, H., Wada, M., Nishioka, H., Itoh, M., Mizoguchi, A., Aoki, T., Fujimoto, T., Matsuda, Y., Tsukita, S., and Takai, Y. (1997) J. Cell Biol. 139, 517-528[Abstract/Free Full Text]
  19. Taya, S., Yamamoto, T., Kano, K., Kawano, Y., Iwamatsu, A., Tsuchiya, T., Tanaka, K., Kanai-Azuma, M., Wood, S. A., Mattick, J. S., and Kaibuchi, K. (1998) J. Cell Biol. 141, 1053-1062[Abstract/Free Full Text]
  20. Picard, V., Ersdal-Badju, E., Lu, A., and Bock, S. C. (1994) Nucleic Acids Res. 22, 2587-2591[Abstract]
  21. Chevray, P. M., and Nathans, D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5789-5793[Abstract]
  22. Klebe, R. J., Hariss, J. V., Sharp, Z. D., and Douglas, M. G. (1983) Gene (Amst.) 25, 333-341[Medline] [Order article via Infotrieve]
  23. Herrmann, C., Horn, G., Spaargaren, M., and Wittinghofer, A. (1996) J. Biol. Chem. 271, 6794-6800[Abstract/Free Full Text]
  24. Ahmadian, M. R., Hoffmann, U., Goody, R. S., and Wittinghofer, A. (1997) Biochemistry 36, 4535-4541[CrossRef][Medline] [Order article via Infotrieve]
  25. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  26. Lenzen, C., Cool, R. H., and Wittinghofer, A. (1995) Methods Enzymol. 225, 95-109
  27. Jaitner, B. K., Becker, J., Linnemann, T., Herrmann, C., Wittinghofer, A., and Block, C. (1997) J. Biol. Chem. 272, 29927-29933[Abstract/Free Full Text]
  28. Ponting, C. P., and Benjamin, D. R. (1996) Trends Biochem. Sci. 21, 422-425[CrossRef][Medline] [Order article via Infotrieve]
  29. Privalov, P. L. (1979) Adv. Protein Chem. 33, 167-186[Medline] [Order article via Infotrieve]
  30. Herrmann, C., and Nassar, N. (1996) Prog. Biophys. Mol. Biol. 66, 1-41[CrossRef][Medline] [Order article via Infotrieve]
  31. White, M. A., Nicolette, C., Minden, A., Polverino, A., Van Aelst, L., Karin, M., and Wigler, M. H. (1995) Cell 80, 533-541[Medline] [Order article via Infotrieve]
  32. Joneson, T., White, M. A., Wigler, M. H., and Bar-Sagi, D. (1996) Science 271, 810-812[Abstract]
  33. Akasaka, K., Tamada, M., Wang, F., Kariya, K., Shima, F., Kikuchi, A., Yamamoto, A., Shirozu, M., Yokoyama, S., and Kataoka, T. (1996) J. Biol. Chem. 271, 5353-5360[Abstract/Free Full Text]
  34. Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., and Der, C. J. (1996) Mol. Cell. Biol. 16, 3923-3933[Abstract]
  35. Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., and Downward, J. (1997) Cell 89, 457-467[Medline] [Order article via Infotrieve]
  36. Marshall, M. S., Davis, L. J., Keys, R. D., Mosser, S. D., Hill, W. S., Scolnick, E. M., and Gibbs, J. B. (1991) Mol. Cell. Biol. 11, 3997-4004[Medline] [Order article via Infotrieve]
  37. Nassar, N., Horn, G., Herrmann, C., Block, C., Jahnknecht, R., and Wittinghofer, A. (1996) Nat. Struct. Biol. 3, 723-729[Medline] [Order article via Infotrieve]
  38. Shirouzu, M., Koide, H., Fujita-Yoshigaki, J., Oshio, H., Toyama, Y., Yamasaki, K., Fuhrman, S. A., Villafranka, E., Kaziro, Y., and Yokoyama, S. (1994) Oncogene 9, 2153-2157[Medline] [Order article via Infotrieve]
  39. Huang, L., Hofer, F., Martin, G. S., and Kim, S. H. (1998) Nat. Struct. Biol. 5, 422-426[Medline] [Order article via Infotrieve]
  40. Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., and Wittinghofer, A. (1997) Science 277, 333-338[Abstract/Free Full Text]
  41. Gorman, C., Skinner, R. H., Skelly, J. V., Neidle, S., and Lowe, P. N. (1996) J. Biol. Chem. 271, 6713-6719[Abstract/Free Full Text]
  42. Sydor, J. R., Engelhardt, M., Wittinghofer, A., Goody, R. S., and Herrmann, C. (1998) Biochemistry 37, 14292-14299[CrossRef][Medline] [Order article via Infotrieve]
  43. Geyer, M., Herrmann, C., Wollgemuth, S., Wittinghofer, A., and Kalbitzer, H. R. (1997) Nat. Struct. Biol. 4, 694-699[Medline] [Order article via Infotrieve]
  44. York, R. D., Yao, H., Dillon, T., Ellig, C. L., Eckert, S. P., McCleskey, E. W., and Stork, P. J. S. (1998) Nature 392, 622-626[CrossRef][Medline] [Order article via Infotrieve]
  45. Cox, A. D., Brtva, T. R., Lowe, D. G., and Der, C. J. (1994) Oncogene 9, 3281-3288[Medline] [Order article via Infotrieve]
  46. Graham, S. M., Cox, A. D., Drivas, G., Rush, M. G., D'Eustachio, P., and Der, C. J. (1994) Mol. Cell. Biol. 14, 4108-4115[Abstract]
  47. McCabe, P. C., Haubruck, H., Plakis, P., McCormick, F., and Innis, M. A. (1992) Mol. Cell. Biol. 12, 4084-4092[Abstract]
  48. Park, H., Bi, E., Pringle, J. R., and Herskowitz, I. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4463-4468[Abstract/Free Full Text]
  49. Ito, S., Matsui, Y., Tohe, A., Harashima, T., and Inoue, H. (1997) Mol. Gen. Genet. 225, 429-437[CrossRef]
  50. Rebstein, P. J., Cardelli, J., Weeks, G., and Spiegelman, G. B. (1997) Exp. Cell Res. 231, 276-283[CrossRef][Medline] [Order article via Infotrieve]
  51. Yoshida, Y., Kawata, M., Miura, Y., Musha, T., Sasaki, T., Kikuchi, A., and Takai, Y. (1992) Mol. Cell. Biol. 12, 3407-3414[Abstract]
  52. Pawson, T. (1995) Nature 373, 573-580[CrossRef][Medline] [Order article via Infotrieve]
  53. Bork, P., Schultz, J., and Ponting, C. P. (1997) Trends Biochem. Sci. 22, 296-298[CrossRef][Medline] [Order article via Infotrieve]
  54. Block, C., Janknecht, R., Herrmann, C., Nassar, N., and Wittinghofer, A. (1996) Nat. Struct. Biol. 3, 244-251[Medline] [Order article via Infotrieve]
  55. Daub, M., Jöckel, J., Quack, T., Weber, C. K., Schmitz, F., Rapp, U. R., Wittinghofer, A., and Block, C. (1998) Mol. Cell. Biol. 18, 6698-6710[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.